NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $172.07
  • Forecasted Upside: 4.27 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$165.02
▲ +1.76 (1.08%)
1 month | 3 months | 12 months
Get New Alnylam Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$172.07
▲ +4.27% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Alnylam Pharmaceuticals in the last 3 months. The average price target is $172.07, with a high forecast of $235.00 and a low forecast of $91.00. The average price target represents a 4.27% upside from the last price of $165.02.

Buy

The current consensus among 15 contributing investment analysts is to buy stock in Alnylam Pharmaceuticals. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 1 sell ratings
12/21/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 1 sell ratings
3/20/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 1 sell ratings
6/18/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 1 sell ratings
9/16/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 8 hold ratings
  • 1 sell ratings
12/15/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 9 hold ratings
  • 1 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 0 sell ratings
5/14/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2021Morgan StanleyLower Price TargetOverweight$206.00 ➝ $205.00Low
i
4/20/2021Needham & Company LLCReiterated RatingBuyLow
i
3/1/2021GuggenheimReiterated RatingBuy ➝ Neutral$162.00Low
i
2/22/2021GuggenheimDowngradeBuy ➝ Neutral$162.00Medium
i
2/14/2021Royal Bank of CanadaReiterated RatingHoldLow
i
2/12/2021Needham & Company LLCBoost Price TargetBuy$160.00 ➝ $180.00Low
i
2/12/2021Morgan StanleyBoost Price TargetOverweight$203.00 ➝ $206.00Low
i
2/12/2021CitigroupDowngradeBuy ➝ Neutral$170.00 ➝ $175.00Low
i
2/12/2021BarclaysBoost Price TargetOverweight$162.00 ➝ $196.00Low
i
2/12/2021HC WainwrightBoost Price TargetBuy$225.00 ➝ $235.00Low
i
Rating by P. Trucchio at HC Wainwright
1/25/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$185.00 ➝ $185.00High
i
1/13/2021CowenBoost Price TargetIn-Line ➝ Outperform$154.00 ➝ $197.00High
i
1/8/2021HC WainwrightReiterated RatingBuy$225.00High
i
Rating by P. Trucchio at HC Wainwright
12/21/2020Royal Bank of CanadaLower Price TargetSector Perform$150.00 ➝ $144.00Medium
i
12/17/2020Piper SandlerBoost Price TargetOverweight$169.00 ➝ $181.00Low
i
11/25/2020BMO Capital MarketsBoost Price Target$182.00 ➝ $183.00Low
i
11/25/2020Morgan StanleyBoost Price TargetOverweight$200.00 ➝ $203.00Low
i
11/24/2020SVB LeerinkBoost Price TargetMarket Perform$90.00 ➝ $91.00Low
i
11/6/2020Morgan StanleyBoost Price TargetOverweight$197.00 ➝ $200.00High
i
10/15/2020Bank of AmericaLower Price TargetBuy$160.00 ➝ $157.00Low
i
10/12/2020Chardan CapitalReiterated RatingBuyLow
i
9/30/2020OppenheimerReiterated RatingHold$156.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
9/30/2020Berenberg BankInitiated CoverageHold$145.00Medium
i
9/8/2020CitigroupInitiated CoverageBuy$170.00 ➝ $170.00Low
i
8/24/2020HC WainwrightReiterated RatingBuyLow
i
Rating by P. Trucchio at HC Wainwright
8/11/2020OppenheimerDowngradeOutperform ➝ Market Perform$162.00 ➝ $156.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
8/7/2020Morgan StanleyLower Price TargetOverweight$199.00 ➝ $197.00Low
i
8/7/2020Chardan CapitalReiterated RatingBuyLow
i
8/7/2020SVB LeerinkBoost Price TargetMarket Perform$89.00 ➝ $90.00Low
i
7/20/2020BMO Capital MarketsBoost Price TargetOutperform$173.00 ➝ $196.00High
i
7/15/2020Morgan StanleyBoost Price TargetOverweight$162.00 ➝ $199.00Low
i
5/28/2020UBS GroupBoost Price TargetNeutral$111.00 ➝ $122.00Low
i
5/12/2020Royal Bank of CanadaInitiated CoverageSector Perform$150.00Medium
i
5/7/2020BMO Capital MarketsBoost Price TargetOutperform$145.00 ➝ $171.00Low
i
5/7/2020OppenheimerBoost Price TargetOutperform$140.00 ➝ $162.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
5/7/2020Morgan StanleyBoost Price TargetOverweight$148.00 ➝ $162.00High
i
5/7/2020BarclaysBoost Price TargetOverweight$143.00 ➝ $156.00High
i
5/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$133.00 ➝ $137.00High
i
5/6/2020Needham & Company LLCBoost Price TargetBuy$135.00 ➝ $160.00High
i
Rating by Alan Carr at Needham & Company LLC
4/24/2020Evercore ISIInitiated CoverageBuy$160.00Low
i
Rating by Maneka Mirchandaney at Evercore ISI
4/14/2020Needham & Company LLCReiterated RatingBuy$135.00High
i
Rating by Alan Carr at Needham & Company LLC
4/14/2020Cantor FitzgeraldBoost Price Target$195.00 ➝ $202.00Low
i
Rating by Alethia Young at Cantor Fitzgerald
4/14/2020Piper SandlerLower Price Target$147.00 ➝ $142.00Medium
i
Rating by Edward Tenthoff at Piper Sandler
4/14/2020Nomura SecuritiesLower Price TargetReduce$75.00 ➝ $74.00Medium
i
4/13/2020OppenheimerReiterated RatingBuy$140.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
3/19/2020Berenberg BankInitiated CoverageBuy$200.00Low
i
3/5/2020CowenReiterated RatingBuyMedium
i
3/3/2020Piper SandlerReiterated RatingBuy$155.00N/A
i
Rating by Edward Tenthoff at Piper Sandler
2/11/2020Nomura SecuritiesBoost Price TargetReduce$62.00 ➝ $75.00Medium
i
Rating by Christopher Marai at Nomura Securities
2/9/2020CowenReiterated RatingBuy$154.00High
i
2/7/2020Evercore ISIInitiated CoverageBuy$145.00High
i
Rating by Maneka Mirchandaney at Evercore ISI
2/7/2020Morgan StanleyLower Price TargetOverweight$150.00 ➝ $148.00Medium
i
2/7/2020Chardan CapitalReiterated RatingBuyHigh
i
2/7/2020Needham & Company LLCReiterated RatingBuyHigh
i
Rating by Alan Carr at Needham & Company LLC
12/19/2019Chardan CapitalBoost Price TargetBuy$150.00 ➝ $190.00Low
i
12/18/2019Nomura SecuritiesReiterated RatingSell$62.00Low
i
Rating by Christopher Marai at Nomura Securities
12/18/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$159.00 ➝ $176.00Medium
i
Rating by Alethia Young at Cantor Fitzgerald
12/17/2019Piper Jaffray CompaniesBoost Price TargetOverweight$145.00 ➝ $155.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
12/17/2019Morgan StanleyBoost Price TargetOverweight$141.00 ➝ $150.00High
i
11/27/2019Cantor FitzgeraldBoost Price Target$150.00 ➝ $159.00Low
i
Rating by Alethia Young at Cantor Fitzgerald
11/21/2019BMO Capital MarketsBoost Price TargetOutperform$128.00 ➝ $138.00High
i
11/21/2019BarclaysBoost Price TargetOverweight$125.00 ➝ $131.00High
i
11/21/2019Needham & Company LLCInitiated CoverageBuy$135.00Low
i
Rating by Alan Carr at Needham & Company LLC
11/21/2019Cantor FitzgeraldReiterated RatingBuy$150.00 ➝ $159.00Low
i
Rating by Alethia Young at Cantor Fitzgerald
11/19/2019OppenheimerInitiated CoverageOutperform$128.00 ➝ $128.00High
i
11/18/2019CowenReiterated RatingBuy$120.00High
i
11/13/2019Bank of AmericaInitiated CoverageBuy$110.00Low
i
10/31/2019Needham & Company LLCReiterated RatingBuy$135.00Low
i
10/8/2019Nomura SecuritiesSet Price TargetSell$62.00Low
i
Rating by Christopher Marai at Nomura Securities
9/10/2019Piper Jaffray CompaniesSet Price TargetBuy$145.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/4/2019UBS GroupBoost Price TargetNeutral$95.00 ➝ $96.00Low
i
9/3/2019Stifel NicolausSet Price TargetBuy$116.00Low
i
Rating by Paul Matteis at Stifel Nicolaus
9/3/2019Piper Jaffray CompaniesBoost Price TargetOverweight$142.00 ➝ $145.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/26/2019Piper Jaffray CompaniesSet Price TargetBuy$142.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/7/2019BarclaysReiterated RatingBuy$125.00High
i
8/7/2019Morgan StanleyLower Price TargetOverweight$126.00 ➝ $124.00High
i
Rating by David Lebovitz at Morgan Stanley
8/7/2019CowenLower Price TargetOutperform$147.00 ➝ $120.00High
i
5/23/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$80.00Medium
i
5/2/2019Morgan StanleySet Price TargetBuy$126.00High
i
Rating by David Lebovitz at Morgan Stanley
5/2/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$126.00 ➝ $128.00High
i
4/15/2019Stifel NicolausBoost Price TargetBuy ➝ Buy$110.00 ➝ $116.00Low
i
4/15/2019Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$135.00 ➝ $138.00Low
i
4/15/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$119.00 ➝ $126.00Low
i
4/11/2019Evercore ISIInitiated CoverageOutperform$120.00Medium
i
4/9/2019SVB LeerinkBoost Price TargetMarket Perform$90.00Medium
i
Rating by M. Foroohar at SVB Leerink LLC
4/9/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$106.00 ➝ $119.00High
i
4/9/2019Cantor FitzgeraldReiterated RatingBuy$135.00Medium
i
4/9/2019Chardan CapitalReiterated RatingBuy$150.00Medium
i
3/6/2019CowenReiterated RatingBuyLow
i
3/6/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
i
3/5/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$122.00Low
i
2/8/2019Needham & Company LLCReiterated RatingBuy$135.00High
i
Rating by Alan Carr at Needham & Company LLC
2/8/2019BMO Capital MarketsLower Price TargetOutperform$106.00High
i
2/7/2019Cantor FitzgeraldReiterated RatingBuy$135.00High
i
1/23/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$87.00Low
i
1/15/2019Piper Jaffray CompaniesLower Price TargetOverweight$152.00Low
i
12/17/2018GuggenheimInitiated CoverageBuy$105.00Medium
i
Rating by Whitney Ijem at Guggenheim
12/7/2018Cantor FitzgeraldReiterated RatingBuy$135.00High
i
11/27/2018SVB LeerinkInitiated CoverageMarket Perform$63.00Low
i
Rating by M. Foroohar at SVB Leerink LLC
11/8/2018Cantor FitzgeraldReiterated RatingBuyN/A
i
10/18/2018BMO Capital MarketsReiterated RatingBuyHigh
i
10/16/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$125.00 ➝ $124.00Medium
i
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$135.00Low
i
9/28/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$93.00 ➝ $87.00High
i
Rating by David Lebovitz at Morgan Stanley
9/13/2018Needham & Company LLCReiterated RatingBuy$152.00Medium
i
Rating by Alan Carr at Needham & Company LLC
9/13/2018Stifel NicolausReiterated RatingBuy$123.00 ➝ $117.00Medium
i
9/4/2018CowenReiterated RatingBuy$147.00High
i
8/28/2018JMP SecuritiesSet Price TargetBuy$198.00Medium
i
Rating by Konstantinos Aprilakis at JMP Securities
8/27/2018Needham & Company LLCSet Price TargetBuy$152.00Low
i
Rating by Alan Carr at Needham & Company LLC
8/13/2018B. RileyBoost Price TargetBuy ➝ Buy$210.00 ➝ $230.00High
i
8/13/2018Nomura SecuritiesLower Price TargetReduce ➝ Reduce$86.00 ➝ $73.00High
i
8/13/2018Morgan StanleySet Price TargetEqual Weight ➝ Hold$99.00 ➝ $93.00High
i
Rating by David Lebovitz at Morgan Stanley
8/13/2018Needham & Company LLCReiterated RatingBuy$152.00High
i
8/13/2018CowenLower Price TargetOutperform ➝ Outperform$157.00 ➝ $147.00High
i
8/13/2018Stifel NicolausReiterated RatingSell ➝ Buy$125.00 ➝ $123.00Medium
i
8/13/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyLow
i
8/13/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$127.00 ➝ $125.00High
i
8/6/2018Stifel NicolausUpgradeHold ➝ Buy$95.00 ➝ $125.00Low
i
8/6/2018Jefferies Financial GroupReiterated RatingBuy$149.00Low
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
8/6/2018JMP SecuritiesSet Price TargetBuy$207.00Medium
i
Rating by Konstantinos Aprilakis at JMP Securities
8/3/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$107.00 ➝ $99.00High
i
8/3/2018Chardan CapitalReiterated RatingBuy$180.00High
i
8/3/2018BMO Capital MarketsReiterated RatingBuy$127.00High
i
8/2/2018CowenReiterated RatingBuy$157.00High
i
7/23/2018Piper Jaffray CompaniesReiterated RatingOverweightLow
i
6/27/2018Piper Jaffray CompaniesLower Price TargetOverweight$182.00 ➝ $160.00Medium
i
5/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$118.00Medium
i
5/4/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$160.00 ➝ $134.00N/A
i
5/4/2018Stifel NicolausLower Price TargetHold ➝ Hold$107.00 ➝ $95.00High
i
4/2/2018B. RileyReiterated RatingBuy$200.00Medium
i
Rating by M. Kumar at B. Riley
4/2/2018Jefferies Financial GroupReiterated RatingBuyHigh
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
3/28/2018Evercore ISIInitiated CoverageIn ➝ line$131.18 ➝ $143.00Medium
i
3/26/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$169.00 ➝ $207.00Low
i
3/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$151.00 ➝ $154.00High
i
Rating by Alethia Young at Credit Suisse Group AG
2/16/2018B. RileyLower Price TargetBuy ➝ Buy$205.00 ➝ $200.00Medium
i
Rating by M. Kumar at B. Riley
2/9/2018Credit Suisse GroupSet Price TargetBuy$151.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
2/9/2018Jefferies Financial GroupSet Price TargetBuy$156.00Low
i
Rating by Eun Yang at Jefferies Financial Group Inc.
2/9/2018Nomura SecuritiesBoost Price TargetSell$86.00Low
i
2/9/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$165.00 ➝ $160.00Medium
i
2/9/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$128.00 ➝ $118.00Medium
i
1/25/2018SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$132.00 ➝ $135.00Low
i
1/19/2018B. RileyReiterated RatingBuy$205.00Low
i
Rating by M. Kumar at B. Riley
1/19/2018Chardan CapitalReiterated RatingBuyLow
i
Rating by G. Amusa at Chardan Capital
1/8/2018B. RileyReiterated RatingBuy ➝ Buy$220.00 ➝ $205.00Medium
i
Rating by M. Kumar at B. Riley
1/7/2018Piper Jaffray CompaniesReiterated RatingBuy$182.00Medium
i
12/15/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
i
12/11/2017B. RileyReiterated RatingBuy$220.00Low
i
Rating by M. Kumar at B. Riley
11/17/2017Piper Jaffray CompaniesReiterated RatingBuy$182.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/9/2017CowenReiterated RatingBuy$151.00N/A
i
11/9/2017Morgan StanleyBoost Price TargetEqual Weight$101.00 ➝ $130.00N/A
i
11/9/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
11/8/2017B. RileyLower Price TargetBuy$220.00N/A
i
Rating by M. Kumar at B. Riley
11/8/2017BarclaysBoost Price TargetOverweight$127.00 ➝ $158.00N/A
i
11/3/2017Credit Suisse GroupBoost Price TargetOutperform$123.00 ➝ $151.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
11/3/2017CowenReiterated RatingOutperform$117.00 ➝ $151.00N/A
i
11/3/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$125.00 ➝ $152.00N/A
i
11/2/2017Piper Jaffray CompaniesReiterated RatingOverweight$188.00 ➝ $14.71N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/1/2017B. RileyInitiated CoverageBuy$150.00 ➝ $240.00N/A
i
Rating by M. Kumar at B. Riley
10/30/2017(FBRC)Initiated CoverageBuy ➝ Buy$150.00N/A
i
Rating by M. Kumar at (FBRC)
10/2/2017The Goldman Sachs GroupUpgradeNeutral ➝ Buy$62.00 ➝ $163.00Medium
i
9/26/2017Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$102.00 ➝ $130.00Low
i
Rating by Eun Yang at Jefferies Financial Group Inc.
9/25/2017Chardan CapitalReiterated RatingBuy$124.00Low
i
Rating by G. Amusa at Chardan Capital
9/22/2017BMO Capital MarketsReiterated RatingOutperform$99.00 ➝ $134.00Low
i
9/21/2017LADENBURG THALM/SH SHReiterated RatingBuy$90.00 ➝ $146.00Low
i
Rating by Christopher James at LADENBURG THALM/SH SH
9/21/2017Sanford C. BernsteinReiterated RatingOutperform ➝ Buy$94.00 ➝ $135.00Low
i
9/20/2017Stifel NicolausReiterated RatingHold$56.00 ➝ $83.00Low
i
9/20/2017CowenReiterated RatingOutperform$93.00 ➝ $117.00Low
i
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$110.00 ➝ $116.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/20/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$85.00 ➝ $125.00Low
i
9/20/2017JMP SecuritiesBoost Price TargetOutperform$101.00 ➝ $128.00Low
i
9/18/2017Jefferies Financial GroupReiterated RatingBuy$102.00Low
i
Rating by Eun Yang at Jefferies Financial Group Inc.
9/15/2017Nomura InstinetInitiated CoverageReduce ➝ Reduce$56.00Low
i
9/14/2017Nomura SecuritiesInitiated CoverageReduce$56.00High
i
9/11/2017Chardan CapitalReiterated RatingBuyHigh
i
Rating by Madhu Kumar at Chardan Capital
9/8/2017SVB LeerinkReiterated RatingMarket Perform$83.00 ➝ $72.00Low
i
9/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$126.00 ➝ $110.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/7/2017Needham & Company LLCReiterated RatingBuy$98.00 ➝ $85.00Low
i
9/7/2017BarclaysReiterated RatingEqual Weight ➝ Overweight$80.00 ➝ $105.00High
i
9/6/2017BMO Capital MarketsReiterated RatingOutperform$105.00 ➝ $99.00Low
i
8/25/2017Jefferies Financial GroupSet Price TargetBuy$102.00Low
i
8/11/2017Credit Suisse GroupReiterated RatingBuy$96.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
8/10/2017Stifel NicolausReiterated RatingBuy$47.00 ➝ $56.00Medium
i
8/10/2017Chardan CapitalReiterated RatingBuy$131.00 ➝ $124.00Medium
i
Rating by Madhu Kumar at Chardan Capital
8/10/2017Morgan StanleyBoost Price TargetEqual Weight$46.00 ➝ $50.00Medium
i
8/10/2017BarclaysBoost Price TargetEqual Weight$50.00 ➝ $70.00High
i
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$99.00High
i
7/17/2017LADENBURG THALM/SH SHSet Price TargetBuy ➝ Buy$80.00 ➝ $90.00Low
i
Rating by Christopher James at LADENBURG THALM/SH SH
7/11/2017CowenReiterated RatingBuy$100.00Low
i
7/11/2017Credit Suisse GroupSet Price TargetBuy$96.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
7/10/2017Morgan StanleyReiterated RatingEqual WeightLow
i
7/10/2017Needham & Company LLCReiterated RatingBuy$98.00Low
i
7/10/2017Chardan CapitalReiterated RatingBuy$110.00 ➝ $131.00High
i
Rating by Madhu Kumar at Chardan Capital
6/27/2017Credit Suisse GroupBoost Price TargetOutperform$90.00 ➝ $96.00High
i
Rating by Alethia Young at Credit Suisse Group AG
6/27/2017Needham & Company LLCBoost Price TargetBuy$68.00 ➝ $98.00High
i
6/26/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
6/22/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$102.00Low
i
6/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$116.00 ➝ $126.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
6/12/2017Chardan CapitalSet Price TargetBuy$110.00Low
i
Rating by Madhu Kumar at Chardan Capital
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform ➝ Sell$69.70 ➝ $67.00Low
i
5/24/2017Piper Jaffray CompaniesSet Price TargetBuy$116.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
5/17/2017LADENBURG THALM/SH SHSet Price TargetBuy$75.00 ➝ $80.00Medium
i
Rating by Christopher James at LADENBURG THALM/SH SH
5/17/2017The Goldman Sachs GroupReiterated RatingNeutral$44.00 ➝ $64.00Medium
i
5/17/2017Credit Suisse GroupReiterated RatingOutperform$50.00 ➝ $90.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
5/17/2017SVB LeerinkReiterated RatingMarket Perform$53.00 ➝ $67.00High
i
5/17/2017CowenReiterated RatingOutperform$100.00Low
i
5/15/2017Piper Jaffray CompaniesSet Price TargetBuy$118.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
5/15/2017Chardan CapitalLower Price TargetBuy$110.00 ➝ $95.00High
i
Rating by Madhu Kumar at Chardan Capital
5/9/2017Credit Suisse GroupReiterated RatingHold$50.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
5/8/2017Morgan StanleyBoost Price TargetEqual Weight$39.00 ➝ $42.00Low
i
5/5/2017Chardan CapitalSet Price TargetBuy$97.00 ➝ $95.00Low
i
Rating by Madhu Kumar at Chardan Capital
4/17/2017BMO Capital MarketsInitiated CoverageOutperform$73.00Medium
i
3/29/2017UBS GroupInitiated CoverageNeutral ➝ Neutral$55.00N/A
i
3/20/2017Credit Suisse GroupDowngradeHold$50.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
3/20/2017(FBRC)Reiterated RatingBuyHigh
i
Rating by R. Jasuja at (FBRC)
3/7/2017(FBRC)Reiterated RatingOutperformLow
i
Rating by R. Jasuja at (FBRC)
2/9/2017Needham & Company LLCReiterated RatingBuy$98.00 ➝ $68.00N/A
i
2/3/2017JMP SecuritiesSet Price TargetBuy$69.00N/A
i
Rating by Michael King at JMP Securities
2/2/2017LADENBURG THALM/SH SHInitiated CoverageBuy$75.00N/A
i
1/9/2017Chardan CapitalBoost Price TargetBuy$69.00 ➝ $97.00N/A
i
Rating by Madhu Kumar at Chardan Capital
12/25/2016Credit Suisse GroupSet Price TargetBuy$50.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
12/20/2016Needham & Company LLCReiterated RatingBuy$98.00N/A
i
12/19/2016Chardan CapitalLower Price TargetBuy$89.00 ➝ $69.00N/A
i
12/6/2016Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Alan Carr at Needham & Company LLC
12/5/2016Chardan CapitalReiterated RatingPositive$89.00N/A
i
12/1/2016Jefferies Financial GroupSet Price TargetBuy$58.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
11/30/2016Chardan CapitalBoost Price TargetBuy$73.00 ➝ $89.00N/A
i
11/24/2016Jefferies Financial GroupSet Price TargetBuy$58.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
11/16/2016Needham & Company LLCReiterated RatingBuy$137.00 ➝ $98.00N/A
i
Rating by Alan Carr at Needham & Company LLC
11/10/2016SVB LeerinkReiterated RatingMarket Perform$43.00N/A
i
Rating by M. Schmidt at SVB Leerink LLC
11/7/2016Credit Suisse GroupReiterated RatingBuy$50.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
11/3/2016(FBRC)Reiterated RatingBuy$100.00N/A
i
Rating by Christopher James at (FBRC)
11/3/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
11/3/2016BarclaysReiterated RatingHold$50.00N/A
i
10/24/2016Piper Jaffray CompaniesReiterated RatingOverweight$106.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
10/8/2016CowenReiterated RatingOutperform$150.00 ➝ $100.00N/A
i
Rating by Ritu Baral at Cowen Inc
10/7/2016Morgan StanleyDowngradeOverweight ➝ Equal Weight$38.00 ➝ $36.00N/A
i
Rating by matthew harrison at Morgan Stanley
10/6/2016Piper Jaffray CompaniesSet Price TargetBuy$106.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
10/6/2016(FBRC)Lower Price TargetOutperform$180.00 ➝ $100.00N/A
i
Rating by christopher james at (FBRC)
10/6/2016The Goldman Sachs GroupLower Price TargetNeutral$65.00 ➝ $34.00N/A
i
10/6/2016Stifel NicolausLower Price TargetHold$68.00 ➝ $36.00N/A
i
10/6/2016Jefferies Financial GroupLower Price TargetBuy$86.00 ➝ $58.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
10/6/2016Needham & Company LLCDowngradeBuy$152.00 ➝ $137.00N/A
i
Rating by Alan Carr at Needham & Company LLC
10/6/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$83.00 ➝ $51.00N/A
i
10/6/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$107.00 ➝ $40.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
10/6/2016BarclaysDowngradeOverweight ➝ Equal Weight$85.00 ➝ $50.00N/A
i
9/30/2016Credit Suisse GroupSet Price TargetBuy$145.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
9/28/2016Jefferies Financial GroupSet Price TargetBuy$86.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$74.00N/A
i
9/27/2016(FBRC)Reiterated RatingOutperform$180.00N/A
i
Rating by christopher james at (FBRC)
9/26/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Michael Schmidt at SVB Leerink LLC
9/8/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by christopher james at (FBRC)
9/6/2016Morgan StanleySet Price TargetBuy$93.00N/A
i
Rating by matthew harrison at Morgan Stanley
8/10/2016The Goldman Sachs GroupReiterated RatingNeutral$63.00 ➝ $65.00N/A
i
8/7/2016CowenReiterated RatingBuy$150.00N/A
i
Rating by Ritu Baral at Cowen Inc
8/5/2016Needham & Company LLCReiterated RatingBuy$152.00N/A
i
Rating by Alan Carr at Needham & Company LLC
8/5/2016JPMorgan Chase & Co.Boost Price TargetOverweight$80.00 ➝ $83.00N/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
8/5/2016Jefferies Financial GroupBoost Price TargetBuy$80.00 ➝ $86.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
8/2/2016Morgan StanleyInitiated CoverageOverweight$93.00N/A
i
7/25/2016Needham & Company LLCReiterated RatingBuy$152.00N/A
i
Rating by Alan Carr at Needham & Company LLC
7/19/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Michael Schmidt at SVB Leerink LLC
7/17/2016(FBRC)Reiterated RatingOutperform$180.00N/A
i
Rating by Christopher James at (FBRC)
7/11/2016Chardan CapitalReiterated RatingBuyN/A
i
7/10/2016JMP SecuritiesReiterated RatingBuyN/A
i
7/5/2016CowenReiterated RatingBuy$150.00N/A
i
Rating by Ritu Baral at Cowen Inc
7/5/2016(FBRC)Reiterated RatingOutperform$180.00N/A
i
Rating by Christopher James at (FBRC)
7/1/2016Needham & Company LLCReiterated RatingBuy$152.00N/A
i
Rating by Alan Carr at Needham & Company LLC
6/30/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
6/23/2016JMP SecuritiesReiterated RatingBuy$127.00N/A
i
(Data available from 6/14/2016 forward)
Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $165.02
$161.76
$165.33

50 Day Range

MA: $140.10
$128.63
$165.02

52 Week Range

Now: $165.02
$119.29
$178.41

Volume

712,500 shs

Average Volume

621,015 shs

Market Capitalization

$19.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Alnylam Pharmaceuticals in the last year: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Chardan Capital, Citigroup Inc., Cowen Inc, Guggenheim, HC Wainwright, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, and SVB Leerink LLC.
View the latest analyst ratings for ALNY.

What is the current price target for Alnylam Pharmaceuticals?

14 Wall Street analysts have set twelve-month price targets for Alnylam Pharmaceuticals in the last year. Their average twelve-month price target is $172.07, suggesting a possible upside of 4.3%. HC Wainwright has the highest price target set, predicting ALNY will reach $235.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $91.00 for Alnylam Pharmaceuticals in the next year.
View the latest price targets for ALNY.

What is the current consensus analyst rating for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals currently has 7 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALNY will outperform the market and that investors should add to their positions of Alnylam Pharmaceuticals.
View the latest ratings for ALNY.

What other companies compete with Alnylam Pharmaceuticals?

How do I contact Alnylam Pharmaceuticals' investor relations team?

Alnylam Pharmaceuticals' physical mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is 617-551-8200 and its investor relations email address is [email protected] The official website for Alnylam Pharmaceuticals is www.alnylam.com.